MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Aandelen Lijst・Fate Therapeutics Inc

Fate Therapeutics Inc

Gesloten

SectorGezondheidszorg

1.2 15.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.16

Max

1.21

Belangrijke statistieken
By Trading Economics
Inkomsten	1.8M -32M
Verkoop	-166K 1.7M
Winstmarge	-1,852.384
Werknemers	181
EBITDA	7.9M -29M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+289.92% upside

Dividenden
By Dow Jones
Volgende Winsten	3 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-2.3M 123M
Vorige openingsprijs	-14.18
Vorige sluitingsprijs	1.2

Nieuwssentiment

By Acuity

60%

40%

293 / 361 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.9101 / 1.14 Steun & Weerstand

Fate Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 jan 2026, 23:29 UTC

Populaire aandelen

Stocks to Watch: Atossa Therapeutics, Union Pacific

18 jan 2026, 23:57 UTC

Acquisities, Fusies, Overnames

Elliott: Standalone Plan Offers Clear Path to Valuation of More Than Y40,000 a Share by 2028

18 jan 2026, 23:57 UTC

Acquisities, Fusies, Overnames

Elliott: Opposing Toyota Fudosan's Revised Tender Offer for Toyota Industries

18 jan 2026, 23:55 UTC

Marktinformatie

Oil Falls as Middle East Tensions Continue to Fade -- Market Talk

18 jan 2026, 23:40 UTC

Marktinformatie

Precious Metals Climb After Trump Threatens Europe With Tariffs Over Greenland -- Market Talk

18 jan 2026, 22:29 UTC

Marktinformatie

Miners Seen Extending Rally as Generalist Investors Warm to Sector -- Market Talk

18 jan 2026, 21:03 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 jan 2026, 21:03 UTC

Marktinformatie

More Australian Voters Switch Away From Major Parties -- Market Talk

18 jan 2026, 19:46 UTC

Marktinformatie

FX Markets Taking Latest Trump Tariff Threat Calmly -- Market Talk

17 jan 2026, 15:06 UTC

Acquisities, Fusies, Overnames

Trump Purchased Netflix, Warner Bonds in Days After Deal Announcement -- Update

17 jan 2026, 03:10 UTC

Acquisities, Fusies, Overnames

Trump Purchased Netflix, Warner Bonds In Days After Deal Announcement -- WSJ

16 jan 2026, 22:48 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 jan 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

16 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

16 jan 2026, 21:48 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 jan 2026, 21:41 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 jan 2026, 21:38 UTC

Acquisities, Fusies, Overnames

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 jan 2026, 21:30 UTC

Acquisities, Fusies, Overnames

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 jan 2026, 20:44 UTC

Winsten

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 jan 2026, 20:42 UTC

Marktinformatie

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 jan 2026, 20:28 UTC

Marktinformatie

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 jan 2026, 19:12 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

Peer Vergelijking

Prijswijziging

Fate Therapeutics Inc Prognose

Koersdoel

By TipRanks

289.92% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4.64 USD 289.92%

Hoogste 8 USD

Laagste 2 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Fate Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Fate Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.9101 / 1.14Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

293 / 361 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.